Sysmex Corporation ADR (OTCMKTS:SSMXY) Short Interest Update

Sysmex Corporation ADR (OTCMKTS:SSMXY) saw a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 41,438 shares, a drop of 36.3% from the February 12th total of 65,013 shares. Based on an average daily volume of 632,342 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the company are short sold. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 632,342 shares, the short-interest ratio is presently 0.1 days.

Sysmex Price Performance

Shares of Sysmex stock opened at $8.67 on Friday. The firm has a fifty day simple moving average of $9.42 and a 200-day simple moving average of $10.55. The company has a current ratio of 3.33, a quick ratio of 2.44 and a debt-to-equity ratio of 0.12. Sysmex has a 1-year low of $8.15 and a 1-year high of $19.85. The stock has a market capitalization of $5.46 billion, a price-to-earnings ratio of 18.06 and a beta of 1.14.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. The business had revenue of $837.32 million during the quarter, compared to the consensus estimate of $819.99 million. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. On average, sell-side analysts expect that Sysmex will post 0.57 earnings per share for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.